3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Recurrence
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Chronic-Phase
2
Leukemia
2
Burkitt Lymphoma
2
Triple Negative Breast Neoplasms
1
Prostate Cancer Recurrent
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Colorectal Neoplasms
1
Blast Crisis
1
Interventions
Bevacizumab
76
Fluorouracil
56
Cetuximab
47
Leucovorin
44
Oxaliplatin
43
pembrolizumab
35
Irinotecan
34
Folfox protocol
24
Capecitabine
24
HMPL-013
22
Specimen Handling
18
trifluridine tipiracil drug combination
16
Nivolumab
15
Blood Specimen Collection
15
Panitumumab
14
regorafenib
13
Magnetic Resonance Spectroscopy
13
Trifluridine
12
Standard of Care
12
Gemcitabine
12
Biopsy
12
Cisplatin
11
sintilimab
10
Interviews as Topic
10
IFL protocol
10
Drug Therapy
10
Carboplatin
9
tislelizumab
8
Trastuzumab
8
Cyclophosphamide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colorectal Neoplasms
×
Dasatinib
×
Clear all
NCT05725200
2023-02-21
EVIDENT
Oslo University Hospital
Phase 2
Recruiting
40 enrolled